Englund J A, Arvin A M, Balfour H H
Department of Laboratory Medicine, University of Minnesota Health Sciences Center, Minneapolis 55455.
J Clin Microbiol. 1990 Oct;28(10):2327-30. doi: 10.1128/jcm.28.10.2327-2330.1990.
The varicella-zoster virus (VZV) membrane glycoprotein gpI elicits a major immunoglobulin G antibody response after naturally acquired VZV infection; antibody to a nonglycosylated immediate-early protein, IE-62 (p170), represents a response to a nonmembrane VZV component. We evaluated antibody response to VZV gpI and IE-62 (p170) at 28 days and 1 year following infection in 34 children (ages 5 to 16 years) enrolled in a randomized placebo-controlled study of oral acyclovir for the treatment of varicella. All children were VZV antibody negative at enrollment, were previously healthy, and had laboratory-documented varicella. Compared with placebo recipients, acyclovir recipients had lower geometric mean titers by the fluorescent antibody to membrane antigen technique at 28 days (620 versus 836) but similar titers at 1 year (122 versus 122). All children had antibodies to gpI and IE-62 detectable by enzyme-linked immunosorbent assay at 28 days and 1 year. No difference in gpI at 28 days compared with 1 year was noted in acyclovir recipients. No difference in antibody to IE-62 (p170) was noted when acyclovir and placebo recipients were compared at either 28 days or 1 year. Antibody responses to gpI and IE were similar when children were stratified by age (5 to 6 years, 7 to 11 years, 12 to 16 years). A short course of oral acyclovir for the treatment of varicella did not affect antibody responses to gpI or IE-62 (p170) in healthy children at 28 days and 1 year following varicella.
水痘带状疱疹病毒（VZV）膜糖蛋白gpI在自然感染VZV后引发主要的免疫球蛋白G抗体反应；针对非糖基化即刻早期蛋白IE-62（p170）的抗体代表了对非膜VZV成分的反应。我们在一项口服阿昔洛韦治疗水痘的随机安慰剂对照研究中，对34名（5至16岁）儿童在感染后28天和1年时对VZV gpI和IE-62（p170）的抗体反应进行了评估。所有儿童在入组时均为VZV抗体阴性，此前身体健康，且有实验室记录的水痘病例。与接受安慰剂的儿童相比，接受阿昔洛韦治疗的儿童在28天时通过膜抗原荧光抗体技术检测到的几何平均滴度较低（620对836），但在1年时滴度相似（122对122）。所有儿童在28天和1年时通过酶联免疫吸附测定均可检测到针对gpI和IE-62的抗体。接受阿昔洛韦治疗的儿童在28天和1年时，gpI水平无差异。在28天或1年时，比较阿昔洛韦和安慰剂接受者，未发现针对IE-62（p170）的抗体有差异。按年龄分层（5至6岁、7至11岁、12至16岁）时，儿童对gpI和IE的抗体反应相似。水痘后28天和1年时，健康儿童短期口服阿昔洛韦治疗水痘不影响对gpI或IE-62（p170）的抗体反应。
